January 15, 2024

Taletrectinib for the treatment of ROS-1 positive non-small cell lung cancer: a drug evaluation of phase I and II data

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Taltrectinib has the potential to improve PFS based on its greater potency against ROS1+ tumors and high CNS penetration. By selectively inhibiting ROS1 wild-type and its resistant mutations over TRKB, taltrectinib has a better safety profile with minimal CNS-related AEs compared to other ROS1+ inhibitors.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Nagasaka et al. (Mon,) studied this question.

synapsesocial.com/papers/690cb5d4f68ca8099a8277d4 https://doi.org/https://doi.org/10.1080/13543784.2024.2305131

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies2020 · 40 citations
2Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer2014 · 1,995 citations
3Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC)2022 · 17 citations
4The effect of TKI therapy and chemotherapy treatment delivery sequence on total progression‑free survival in patients with advanced EGFR‑mutated NSCLC2020 · 6 citations
51373P Efficacy and safety of taletrectinib in patients (Pts) with ROS1+ non-small cell lung cancer (NSCLC): Interim analysis of global TRUST-II study2023 · 12 citations

Preguntar a la IA

Me gusta

Guardar